Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

(2012) Jaafar Bennouna et al.   LANCET ONCOLOGY

Bevacizumab Combined With Chemotherapy in the Second-Line Treatment of Metastatic Colorectal Cancer: Results from the Phase II BEVACOLOR Study

(2011) Jaafar Bennouna et al.   Clinical Colorectal Cancer

Immortal time bias in critical care research: Application of time-varying Cox regression for observational cohort studies*

(2009) Ayumi K. Shintani et al.   CRITICAL CARE MEDICINE

Immortal Person-Time in Studies of Cancer Outcomes

(2009) Timothy L. Lash et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study

(2009) M. Kozloff et al.   ONCOLOGIST

Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)

(2008) Axel Grothey et al.   JOURNAL OF CLINICAL ONCOLOGY

Immortal Time Bias in Pharmacoepidemiology

(2007) S. Suissa   AMERICAN JOURNAL OF EPIDEMIOLOGY